Scintigraphic Imaging of Sarcomatous Tumors with [111In-DTPA-Phe-1]-Octreotide

• Published in: Oncology Vol. 58; no. 1; pp. 18 - 24
• Main Authors: Giannakenas, C., Kalofonos, H.P., Apostolopoulos, D., Petsas, T., Kalogeropoulou, C., Tzorakelefterakis, E., Skopa, C.D., Vassilakos, P.J.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland Karger 01.01.2000; S. Karger AG
• Subjects: AIDS/HIV; Biological and medical sciences; Clinical Study; Female; Human immunodeficiency virus; Humans; Indium Radioisotopes; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Middle Aged; Miscellaneous. Technology; Octreotide - analogs & derivatives; Pentetic Acid - analogs & derivatives; Radionuclide Imaging; Radionuclide investigations; Sarcoma - diagnostic imaging; Octreotide; Sarcomas; Scintigraphy; Somatostatin receptors; Radionuclide study; Performance evaluation; Human; Radiolabelling; Sarcoma; Malignant tumor; Medical imagery; Diagnosis; Somatostatin; Technique; Biological receptor
• ISSN: 0030-2414; 1423-0232
• DOI: 10.1159/000012074

The objective of the present study was to investigate the efficacy of 111 In-DTPA-octreotide (OC) for in vivo scintigraphic imaging of these relatively uncommon tumors. Thirteen patients (9 males, 4 females, mean age 59 years) with known sarcomatous lesions were studied. All patients had known lesions as demonstrated by previous investigation with other modalities, e.g. CAT, MRI. Following intravenous injection of 10 μg of OC labeled with 2.8–4.2 mCi 111 In, planar imaging was done at 6 ± 1 and 22 ± 2 h, respectively. Histologic verification was obtained in all cases, either from fine needle aspiration or from surgically removed tissue. Positive imaging was observed in 12/13 cases (92.3%). One scan was false-negative (7.7%). Occult lesions were demonstrated in two patients. The histologic typing and the scintigraphy results were: fibrosarcoma (1+/1), embryonic rhabdomyosarcoma (1+/1), leiomyosarcomas (3+/3), liposarcomas (2+/2), uterine sarcomas (2+/2), HIV (–) Kaposi sarcoma (1+/1), osteosarcoma (1+/1), chondrosarcoma (1–/1) and neurogenous sarcoma (1+/1). OC appears to have properties that lead to a new indication for its use. Other possible applications relate to the therapeutic use of octreotide either unlabeled or labeled with a beta-emitting radionuclide, as well as its use in radioimmunoguided surgery. Regarding the latter, our preliminary results are encouraging.